By Finance Pulse in Transformative —

AbbVie Expands Portfolio with $20B Acquisitions

AbbVie enhances its drug development pipeline by acquiring Cerevel Therapeutics, ImmunoGen, and Aliada, investing over $20 billion in neuroscience and cancer therapies.

A dynamic and modern illustration featuring abstract representations of neuroscience, cancer, and Al
AbbVie Expands Portfolio with $20B Acquisitions

AbbVie acquired neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen, and Alzheimer's therapy developer Aliada in 2024 for over $20 billion in total.

Source